Entheon Biomedical Corp.

Entheon Biomedical is pioneering a leading-edge addiction recovery solution that harnesses and optimizes the therapeutic potential of the DMT molecule. Entheon exists to invert the addiction-recovery ratio, turning the 'untreatable case' and 'lost cause' from the norm to the exception. We are committed to the legal development of regulated, safe & effective, psychedelic therapies, and in demonstrating their efficacy when administered in a scientifically-validated manner.

Recent News

  • Entheon Biomedical's Wholly-Owned Subsidiary, HaluGen Life Sciences and Silo Wellness Announces Psychedelics Genetic Test Kit Partnership

    Vancouver, British Columbia--(Newsfile Corp. - June 17, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon"), a biotechnology company focused on developing psychedelic medicines to treat addiction, and Silo Wellness Inc. (CSE: SILO) (OTC: SILFF) (FSE:3K70) ("Silo Wellness"), a functional and psilocybin mushroom company and psychedelic wellness retreats operator, have signed a referral agreement (the "Agreement"), to help drive brand awareness of the Psychedelics Genetic Test kit, developed and commercialized by wholly-owned subsidiary HaluGen Life Sciences Inc....

    2021-06-17 8:30 AM EDT
  • Entheon Biomedical Corp. Announces Agreement to Acquire Lobo Genetics Inc.

    Vancouver, British Columbia--(Newsfile Corp. - June 16, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company") is pleased to announce that the Company has entered into a definitive agreement dated June 15, 2021 (the "Agreement") with Lobo Genetics Inc. ("Lobo"), and 13089363 Canada Inc. ("Subco"), a wholly-owned subsidiary of Entheon. Pursuant to the Agreement, Entheon and Lobo will combine their respective businesses by way of a "three-cornered" amalgamation in accordance with section 185...

    2021-06-16 8:30 AM EDT
  • Entheon Biomedical's Wholly-Owned Subsidiary, HaluGen Life Sciences, Psychedelics Genetic Test Kit Now Available for Sale in US

    Vancouver, British Columbia--(Newsfile Corp. - June 10, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced its Psychedelics Genetic Test Kit, developed by its wholly-owned subsidiary, HaluGen Life Sciences Inc. ("HaluGen"), is now available for sale in the United States. The Psychedelics Genetic Test Kit, a first of its kind, was designed and commercialized by HaluGen, and launched in Canada on April...

    2021-06-10 8:30 AM EDT
  • Entheon Biomedical Announces DMT Drug Supply Agreement with Ofichem Group

    Vancouver, British Columbia--(Newsfile Corp. - May 18, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced it has entered into a drug-supply agreement (the "Agreement") with Laboratorium Ofichem BV ("Ofichem" or "Ofichem Group"). Under the terms of the Agreement, Ofichem will supply Entheon with GMP quality N,N-dimethyltryptamine drug substances ("DMT") for upcoming formulation, preclinical, clinical, and post-approval commercialization phases under the European...

    2021-05-18 8:30 AM EDT
  • Entheon Biomedical Corp. Provides Corporate Update

    Launch of Psychedelics DNA Test KitPhase 1 clinical trial for DMT progressing as plannedPre-clinical In Vivo work scheduled to start at Israeli CROStrengthened expertise focused on driving initiatives forwardUpgraded OTC Listing Financial UpdateVancouver, British Columbia--(Newsfile Corp. - May 14, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (OTCQB: ENTBF) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to provide a corporate update on its operations and progress on its strategic...

    2021-05-14 8:30 AM EDT
  • Entheon Biomedical Lists on OTCQB Venture Market

    Vancouver, British Columbia--(Newsfile Corp. - May 5, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: "1XU1") ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that it has been approved for trading on the OTCQB Venture Market ("OTCQB") effective May 5, 2021."We are thrilled to be up-listing on to the OTCQB, which will allow for greater engagement with our U.S. investor base. As we advance our DMT addiction...

    2021-05-05 10:30 AM EDT
  • Entheon Biomedical Corp. Launches HaluGen's Psychedelics Genetic Test

    Vancouver, British Columbia--(Newsfile Corp. - April 6, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announces the launch of the industry's first Psychedelics Genetic Test Kit, developed by wholly-owned subsidiary, HaluGen Life Sciences Inc. ("HaluGen"), and that it is now available for sale within Canada.HaluGen's psychedelic pre-screening platform and DNA testing provides genetic, personal and familial insights to better inform one's psychedelic assisted therapy...

    2021-04-06 8:30 AM EDT
  • Entheon Biomedical Announces Nancy Maher, Special Advisor of Data Science and Regulatory Affairs

    Vancouver, British Columbia--(Newsfile Corp. - March 3, 2021) -  Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce Nancy Maher as Special Advisor of Data Science and Regulatory Affairs, providing expertise on the development of the Company's data strategy design, study design and advise on regulatory relationships and data strategy.Ms. Maher has served as an executive and consultant for major...

    2021-03-03 8:30 AM EST